Project Grant R01HL184892
Award Date 8/5/26
Completion Date 5/31/30
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- The National Institutes of Health National Heart Lung and Blood Institute awarded the Regents of the University of California, San Francisco $813,499 on August 10, 2026, for Project Grant R01HL186881 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research investigating immune exhaustion, telomere length, and immune response effects on diffusing capacity for carbon monoxide (DLCO) in people with HIV, termed the I'M TIRED-HIV Study. Preliminary findings show that...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $795,464 to The Regents of the University of California, San Francisco on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into adaptive-like natural killer cells in pulmonary cytomegalovirus reactivation. The project investigates whether local cytomegalovirus-specific natural killer cell immune responses in the lungs potentiate...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2.98 million Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) to the University of California, San Francisco to conduct a four-year research study examining the impact of asymptomatic cytomegalovirus (CMV) infection on cardiovascular event risk in people with HIV (PWH). The primary deliverable is a large-scale Mendelian randomization study that will assess whether CMV-associated plasma proteomic signatures and...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded National Jewish Health $249,000 on July 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate rare airway cell function in post-viral chronic inflammation. The research examines the role of microfold (M) cells in the post-influenza lung, particularly their contribution to secondary bacterial infection susceptibility and host protection. Using single-nucleus transcriptomic and...
- The National Heart, Lung, and Blood Institute awarded Northern California Institute For Research And Education, Inc. (NCIRE) $3.002 million on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective longitudinal study of cardiac fibro-inflammation progression in women with HIV. The research repeats cardiac magnetic resonance imaging in returning participants approximately eight years after their initial scans, drawing from the MACS-WIHS...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded $877,662 to Weill Medical College of Cornell University on May 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate biomechanical and epigenetic mechanisms by which HIV-infected CD4+ T cells resist killing by cytotoxic T lymphocytes. The funded research addresses how HIV reservoir cells...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco a $3.26 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) for a four-year period beginning September 1, 2025. This research initiative investigates immune activation and region-specific myocardial arrhythmic substrate in sudden cardiac death (SCD) victims with HIV. The study builds upon the investigators'...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital $2,656,944 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 15, 2025, to establish and conduct the Uganda Lung Health Study, a five-year observational cohort investigating the intersection of HIV, sex, and chronic obstructive pulmonary disease risk across the adult lifespan in sub-Saharan Africa. The study will enroll 800 adolescents and adults aged 16–90 years, balanced by sex and...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $354,982 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune mechanisms driving lung fibrosis following severe viral respiratory infections. The research dissects how aberrant immune-epithelial interactions perpetuate post-viral lung damage distinct from idiopathic pulmonary fibrosis. The work focuses on three objectives: defining mechanisms that sustain...